The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials

European Journal of Cancer

Volumn 48, Issue 2, 2012, Pages 187-195

  Yan, Tingting ^a,b   Yin, Wenjin ^a,b   Zhou, Qiong ^a,b   Zhou, Liheng ^a,b   Jiang, Yiwei ^a,b   Du, Yueyao ^a,b   Shao, Zhimin ^a,b   Lu, Jinsong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Adjuvant therapy; Breast neoplasms; Prognosis; Zoledronic acid

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; FEMALE; HUMAN; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84655169571     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.021     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 4 2009 225 249
2. G.D. Roodman Mechanisms of bone metastasis N Engl J Med 350 16 2004 1655 1664
3. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 3 2001 165 176 (Pubitemid 32452017)
4. F. Saad, J.D. Adachi, and J.P. Brown Cancer treatment-induced bone loss in breast and prostate cancer J Clin Oncol 26 33 2008 5465 5476
5. M. Rabaglio, Z. Sun, and K.N. Price Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Ann Oncol 20 9 2009 1489 1498
6. R.E. Coleman, L.M. Banks, and S.I. Girgis Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 2 2007 119 127 (Pubitemid 46158372)
7. R. Eastell, J.E. Adams, and R.E. Coleman Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230 J Clin Oncol 26 7 2008 1051 1057
8. O. Bock, and D. Felsenberg Bisphosphonates in the management of postmenopausal osteoporosis - optimizing efficacy in clinical practice Clin Interv Aging 3 2 2008 279 297 (Pubitemid 352037868)
9. B.E. Hillner, J.N. Ingle, and J.R. Berenson American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel J Clin Oncol 18 6 2000 1378 1391 (Pubitemid 30159858)
10. I. Holen, and R.E. Coleman Bisphosphonates as treatment of bone metastases Curr Pharm Des 16 11 2010 1262 1271
11. D.M. Black, P.D. Delmas, and R. Eastell Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 18 2007 1809 1822 (Pubitemid 46698462)
12. D.L. Hershman, D.J. McMahon, and K.D. Crew Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer J Clin Oncol 26 29 2008 4739 4745
13. Shapiro CL, Halabi S, Gibson G, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 7980. J Clin Oncol, 2008;26(15S (May 20 Supplement)). [abstract no. 512].
14. N.J. Bundred, I.D. Campbell, and N. Davidson Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results Cancer 112 5 2008 1001 1010 (Pubitemid 351304583)
15. M. Gnant, B. Mlineritsch, and G. Luschin-Ebengreuth Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 9 2008 840 849
16. P. Clezardin, F.H. Ebetino, and P.G. Fournier Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity Cancer Res 65 12 2005 4971 4974 (Pubitemid 40827299)
17. Gnant M, Mlineritsch M, Stoeger H, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. ASCO annual meeting 2010; [abstract no. 533].
18. H. Eidtmann, R. de Boer, and N. Bundred Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study Ann Oncol 21 11 2010 2188 2194
19. A.M. Brufsky, L.D. Bosserman, and R.R. Caradonna Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 2 2009 77 85
20. M. Gnant, B. Mlineritsch, and W. Schippinger Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 7 2009 679 691
21. R.E. Coleman, M.C. Winter, and D. Cameron The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 7 2010 1099 1105
22. W.G. Cochran The combination of estimates from different experiments Biometrics 10 1954 101 129
23. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 11 2002 1539 1558 (Pubitemid 34746062)
24. LLombarto A, Frassoldati A, Paija O, et al. Neven; Fundacion Instituto Valenciano de Oncologia, Valencia, Spain; Azienda Ospedaliera Policlinico, Maranello, Italy; Turku University Hospital, Turku, Finland; Ziekenhuis Leyenburg, Den Haag, Netherlands; Centre Hospitalier Universitaire Onc, Liege, Belgium; Virga Jesseziekenhuis, Hasselt, Belgium; AZ Maria Middelares, St. Niklaas, Belgium; Novartis, Florham Park, NJ; UZ Gathuiseberg Dienst Gynaecologische Oncologie, Leuven, Belgium Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Breast cancer symposium; 2009 [abstract no. 213].
25. Coleman RE. Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04). SABCS. [abstract no. P5-11-02 2010].
26. S.G. Senaratne, J.L. Mansi, and K.W. Colston The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells Br J Cancer 86 9 2002 1479 1486 (Pubitemid 34548073)
27. P.D. Ottewell, D.V. Lefley, and S.S. Cross Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model Int J Cancer 126 2 2010 522 532
28. H.L. Neville-Webbe, C.A. Evans, R.E. Coleman, and I. Holen Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro Tumour Biol 27 2 2006 92 103
29. P.D. Ottewell, H. Monkkonen, and M. Jones Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer J Natl Cancer Inst 100 16 2008 1167 1178
30. H.L. Neville-Webbe, A. Rostami-Hodjegan, C.A. Evans, R.E. Coleman, and I. Holen Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells Int J Cancer 113 3 2005 364 371 (Pubitemid 40038702)
31. P.D. Ottewell, B. Deux, and H. Monkkonen Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo Clin Cancer Res 14 14 2008 4658 4666
32. R. Aft, M. Naughton, and K. Trinkaus Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 5 2010 421 428
33. H.L. Neville-Webbe, R.E. Coleman, and I. Holen Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction Br J Cancer 102 6 2010 1010 1017